Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PATRICIA CLEMENT LEE

Allopathic & Osteopathic Physicians Dermatology

NPI
1831335918
CMS profile
264427
Location
WEBSTER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$7,655.63

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,517.06 46
Travel and Lodging $2,638.57 11
Consulting Fee $1,500.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PATRICIA CLEMENT LEE

NPI 1831335918 · CMS profile ID 264427

Allopathic & Osteopathic Physicians / Dermatology

WEBSTER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PATRICIA CLEMENT LEE, NPI 1831335918, CMS profile ID 264427. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PATRICIA CLEMENT LEE, NPI 1831335918, CMS profile ID 264427. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PATRICIA CLEMENT LEE, NPI 1831335918, CMS profile ID 264427, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1831335918?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $7,655.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–58 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $346.5002/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700437919 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $65.0001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700437917 CMS
Janssen Biotech, Inc. $6.6001/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658550655 CMS
PFIZER INC. $494.9401/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671929901 CMS
PFIZER INC. $364.1901/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671929903 CMS
PFIZER INC. $249.4701/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671929905 CMS
PFIZER INC. $241.5001/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671929907 CMS
Sun Pharmaceutical Industries Inc. $79.4301/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704594761 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,655.63 58
PY2020 $896.97 27
PY2021 $3,905.29 73
PY2022 $4,564.78 97
PY2023 $7,170.50 128
PY2024 $5,127.61 109
PY2025 $7,278.11 125

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,472.48 7
PY2025 Principal investigator $738,419.17 172
PY2024 Recipient $7,538.98 6
PY2024 Principal investigator $758,133.92 214
PY2023 Recipient $10,166.24 5
PY2023 Principal investigator $421,943.71 247
PY2022 Recipient $215.00 1
PY2022 Principal investigator $734,300.41 117
PY2021 Recipient $3,287.00 2
PY2021 Principal investigator $1,158,956.90 121
PY2020 Recipient $6,033.30 4
PY2020 Principal investigator $1,446,370.96 178
PY2019 Recipient $9,724.30 2
PY2019 Principal investigator $1,922,759.40 169

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

179 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202534067
Principal investigator 1 Janssen Research & Development, LLC $1,520.00 12/25/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384787
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,125.00 12/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430996
Principal investigator 1 Janssen Research & Development, LLC $3,202.00 12/19/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385081
Principal investigator 1 ABBVIE INC. $185.90 12/18/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202531288
Principal investigator 1 ABBVIE INC. $416.00 12/18/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202531290
Principal investigator 1 Janssen Research & Development, LLC $2,514.00 12/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385102
Principal investigator 1 ABBVIE INC. $1,413.12 12/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202530074
Principal investigator 1 ABBVIE INC. $128.00 12/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202530188
Recipient Regeneron Pharmaceuticals, Inc. $506.21 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119555
Recipient Regeneron Pharmaceuticals, Inc. $105.74 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119557
Recipient Regeneron Pharmaceuticals, Inc. $87.12 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119559
Recipient Regeneron Pharmaceuticals, Inc. $30.42 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119561
Recipient Regeneron Pharmaceuticals, Inc. $76.06 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119563
Recipient Regeneron Pharmaceuticals, Inc. $55.31 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119565
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $945.10 12/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430986
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $600.00 12/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430988
Principal investigator 1 ABBVIE INC. $4,286.10 12/10/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202529882
Principal investigator 1 ABBVIE INC. $3,791.20 12/10/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202529884
Principal investigator 1 ABBVIE INC. $1,134.90 12/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202529746
Principal investigator 1 ABBVIE INC. $3,215.00 12/04/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202527600
Principal investigator 1 ABBVIE INC. $311.84 12/02/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202526282
Recipient Regeneron Pharmaceuticals, Inc. $611.62 12/02/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119553
Principal investigator 1 Janssen Research & Development, LLC $3,040.00 12/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385090
Principal investigator 1 Janssen Research & Development, LLC $4,803.00 12/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385186
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 12/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,928.90 12/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289047
Principal investigator 1 PFIZER INC. $1,606.15 11/26/2025 Non-covered Recipient Entity
Center for Clinical Studies LTD LLP
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228724788
Principal investigator 1 Janssen Research & Development, LLC $7.16 11/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384697
Principal investigator 1 Janssen Research & Development, LLC $7.00 11/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385219
Principal investigator 1 Janssen Research & Development, LLC $21.57 11/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384869
Principal investigator 1 Janssen Research & Development, LLC $260.00 11/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385174
Principal investigator 1 Janssen Research & Development, LLC $300.00 11/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385193
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $45.00 11/12/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288287
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,549.55 11/11/2025 Non-covered Recipient Entity
Center For Clinical Studies
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235998234
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,477.05 11/10/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190313827
Principal investigator 1 ABBVIE INC. $532.00 11/04/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202520825
Principal investigator 1 Janssen Research & Development, LLC $3,366.00 10/31/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175384970
Principal investigator 1 PFIZER INC. $1,902.55 10/31/2025 Non-covered Recipient Entity
Center for Clinical Studies LTD LLP
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228742047
Principal investigator 1 Janssen Research & Development, LLC $6,992.00 10/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384949
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $297.47 10/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287649
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.23 10/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287667
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,828.80 10/22/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287277
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 10/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $385.00 10/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286989
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 10/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286991
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $638.30 10/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430978
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,499.00 10/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430982
Principal investigator 1 ABBVIE INC. $1,399.84 10/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202513811
Principal investigator 1 ABBVIE INC. $3,134.90 10/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202515195
Principal investigator 1 ABBVIE INC. $2,117.00 10/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515197
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $300.00 10/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430976
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,830.00 10/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286573
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 10/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286575
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,947.00 10/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286067
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 09/29/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384805
Principal investigator 1 Janssen Research & Development, LLC $1,681.00 09/29/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384891
Principal investigator 1 Janssen Research & Development, LLC $1,920.00 09/22/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384923
Principal investigator 1 SANOFI US SERVICES INC. $790.00 09/22/2025 Non-covered Recipient Entity
Center For Clinical Studies Ltd Llp
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226084157
Principal investigator 1 PFIZER INC. $4,546.10 09/09/2025 Non-covered Recipient Entity
Center for Clinical Studies LTD LLP
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228750894
Principal investigator 1 Janssen Research & Development, LLC $3,040.00 09/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385040
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 09/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175385065
Principal investigator 1 ABBVIE INC. $2,657.10 09/04/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202509206
Principal investigator 1 ABBVIE INC. $1,293.80 09/04/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509356
Principal investigator 1 Janssen Research & Development, LLC $3,786.00 09/04/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385232
Principal investigator 1 ABBVIE INC. $1,596.00 09/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202507811
Principal investigator 1 ABBVIE INC. $1,399.84 09/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,204.20 09/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285057
Principal investigator 1 Janssen Research & Development, LLC $1,920.00 09/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384821
Principal investigator 1 Janssen Research & Development, LLC $858.00 08/29/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175385129
Principal investigator 1 ABBVIE INC. $13.52 08/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202506465
Principal investigator 1 ABBVIE INC. $1,160.90 08/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202506467
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 08/25/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384843
Principal investigator 1 ABBVIE INC. $28.74 08/22/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202505619
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,254.25 08/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284331
Principal investigator 1 ABBVIE INC. $230.77 08/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202504631
Principal investigator 1 ABBVIE INC. $1,244.40 08/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502478
Principal investigator 1 ABBVIE INC. $3,300.60 08/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202503317
Principal investigator 1 ABBVIE INC. $3,717.60 08/05/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202501290
Principal investigator 1 ABBVIE INC. $2,076.60 08/05/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501996
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 08/04/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175385140
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,295.50 08/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283565
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 08/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283567
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283569
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,400.70 08/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283703
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,948.40 08/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283705
Principal investigator 1 ABBVIE INC. $2,579.20 07/30/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202500504
Principal investigator 1 Janssen Research & Development, LLC $17,353.00 07/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384691
Principal investigator 1 Janssen Research & Development, LLC $24.38 07/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385096
Principal investigator 1 Janssen Research & Development, LLC $3,715.00 07/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385198
Principal investigator 1 ABBVIE INC. $6.03 07/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202498524
Principal investigator 1 ABBVIE INC. $29.39 07/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498528
Principal investigator 1 ABBVIE INC. $19.66 07/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498598
Principal investigator 1 ABBVIE INC. $26.09 07/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498240
Principal investigator 1 ABBVIE INC. $119.93 07/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498276
Principal investigator 1 ABBVIE INC. $2,500.00 07/15/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202498278
Principal investigator 1 Janssen Research & Development, LLC $125.00 07/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384733
Principal investigator 1 Janssen Research & Development, LLC $7.29 07/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384794
Principal investigator 1 Janssen Research & Development, LLC $5.14 07/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175385070
Principal investigator 1 ABBVIE INC. $72.49 07/10/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497972
Principal investigator 1 ABBVIE INC. $5,880.50 07/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497564
Principal investigator 1 ABBVIE INC. $3,321.00 07/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497642
Principal investigator 1 ABBVIE INC. $4,235.30 07/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202497200
Principal investigator 1 ABBVIE INC. $2,538.20 07/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497206
Principal investigator 1 Janssen Research & Development, LLC $18.34 07/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384982
Principal investigator 1 Janssen Research & Development, LLC $11.82 07/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385124
Principal investigator 1 Janssen Research & Development, LLC $6,243.00 07/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385169
Principal investigator 1 ABBVIE INC. $355.66 07/02/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495043
Principal investigator 1 ABBVIE INC. $1,239.20 07/02/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202495061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $550.00 07/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LT
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282022
Principal investigator 1 Janssen Research & Development, LLC $5,248.00 06/30/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385017
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 06/27/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384686
Principal investigator 1 PFIZER INC. $12,435.00 06/26/2025 Non-covered Recipient Entity
Center for Clinical Studies LTD LLP
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228793353
Principal investigator 1 ABBVIE INC. $178.81 06/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202492755
Principal investigator 1 ABBVIE INC. $1,290.90 06/18/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202492045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/18/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223281592
Principal investigator 1 ABBVIE INC. $20.30 06/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202491685
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,986.00 06/13/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223281258
Principal investigator 1 ABBVIE INC. $355.66 06/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202487391
Principal investigator 1 ABBVIE INC. $2,487.20 06/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487565
Principal investigator 1 ABBVIE INC. $532.00 06/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202487567
Principal investigator 1 Janssen Research & Development, LLC $230.00 05/30/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385046
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,911.45 05/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280478
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 05/26/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385034
Principal investigator 1 Eli Lilly and Company $20,802.00 05/23/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187879291
Principal investigator 1 Janssen Research & Development, LLC $5,739.00 05/22/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175384753
Principal investigator 1 Janssen Research & Development, LLC $28.41 05/16/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175385023
Principal investigator 1 Janssen Research & Development, LLC $3,990.00 05/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175384759
Principal investigator 1 Janssen Research & Development, LLC $1,720.00 05/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385004
Principal investigator 1 Janssen Research & Development, LLC $6,549.00 05/09/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385181
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,437.00 05/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430964
Principal investigator 1 ABBVIE INC. $4,908.00 05/07/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482791
Principal investigator 1 ABBVIE INC. $3,782.60 05/07/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202482793
Principal investigator 1 ABBVIE INC. $2,162.82 05/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202481459
Principal investigator 1 ABBVIE INC. $5,546.00 05/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202481461
Principal investigator 1 Eli Lilly and Company $4,820.00 04/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187877087
Principal investigator 1 Janssen Research & Development, LLC $10,530.00 04/28/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384896
Principal investigator 1 Janssen Research & Development, LLC $2,474.00 04/25/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384666
Principal investigator 1 ABBVIE INC. $131.21 04/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202477651
Principal investigator 1 Janssen Research & Development, LLC $19.96 04/14/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385225
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $660.00 04/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277922
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 04/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277924
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,584.30 04/11/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278002
Principal investigator 1 Eli Lilly and Company $6,976.16 04/10/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187878457
Principal investigator 1 Janssen Research & Development, LLC $2,283.00 04/07/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175384936
Principal investigator 1 ABBVIE INC. $1,794.60 04/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202473054
Principal investigator 1 ABBVIE INC. $1,421.20 04/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202473057
Principal investigator 1 ABBVIE INC. $1,365.28 04/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202473061
Principal investigator 1 Janssen Research & Development, LLC $159.00 04/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384712
Principal investigator 1 Janssen Research & Development, LLC $28.74 04/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384992
Principal investigator 1 Novartis Pharmaceuticals Corporation $212,421.98 04/01/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190306581
Principal investigator 1 Janssen Research & Development, LLC $2,318.00 03/27/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175384765
Principal investigator 1 Janssen Research & Development, LLC $30.86 03/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385029
Principal investigator 1 Janssen Research & Development, LLC $3,834.00 03/21/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175385145
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $270.00 03/12/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276327
Principal investigator 1 ABBVIE INC. $1,244.40 03/07/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202460012
Principal investigator 1 ABBVIE INC. $6,330.90 03/07/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M24-727 - A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202460017
Principal investigator 1 ABBVIE INC. $1,064.00 03/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202457186
Principal investigator 1 Janssen Research & Development, LLC $3,760.00 03/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175384929
Principal investigator 1 Janssen Research & Development, LLC $6,095.00 03/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175384776
Principal investigator 1 Janssen Research & Development, LLC $5,573.00 03/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384856
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $28,932.80 02/26/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275607
Principal investigator 1 ABBVIE INC. $3,321.00 02/18/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202452186
Principal investigator 1 Janssen Research & Development, LLC $5,151.00 02/07/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384744
Principal investigator 1 ABBVIE INC. $4,302.00 02/06/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447127
Principal investigator 1 ABBVIE INC. $5,991.90 02/05/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202444131
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,004.95 02/03/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274621
Principal investigator 1 Janssen Research & Development, LLC $5,219.00 01/31/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175385164
Principal investigator 1 Janssen Research & Development, LLC $4,989.00 01/27/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175384975
Principal investigator 1 Janssen Research & Development, LLC $2,918.00 01/24/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175385151
Principal investigator 1 Eli Lilly and Company $5,993.00 01/21/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187875573
Principal investigator 1 Janssen Research & Development, LLC $25.50 01/17/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175384674
Principal investigator 1 SANOFI US SERVICES INC. $4,801.60 01/13/2025 Non-covered Recipient Entity
Center For Clinical Studies Ltd Llp
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226084263
Principal investigator 1 SANOFI US SERVICES INC. $13,880.20 01/13/2025 Non-covered Recipient Entity
Center For Clinical Studies Ltd Llp
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226084266
Principal investigator 1 SANOFI US SERVICES INC. $2,905.30 01/13/2025 Non-covered Recipient Entity
Center For Clinical Studies Ltd Llp
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1226084270
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.30 01/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,499.95 01/08/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223273773
Principal investigator 1 ABBVIE INC. $1,421.20 01/02/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202433721
Principal investigator 1 ABBVIE INC. $2,683.92 01/02/2025 Non-covered Recipient Entity
CENTER FOR CLINICAL STUDIES LTD LLP
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433725